Drawing for BRAINEVER

USPTO serial 79188386

BRAINEVER

Reviewed by CopyMark Law Group

Reg. 5220280Status 709
Filing date
Status date
Registration date
Jun 13, 2017
Examiner
GUTTADAURO, JULIE MARIE
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BRAINEVER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeannine A Rittenhouse

Jeannine A Rittenhouse IpHorgan Ltd.195 Arlington Heights RoadSuite 125Buffalo Grove, IL 60089

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products for the protection, the treatment of brain and spinal cord diseases or degenerative disorders and for improving neurological abilities, pharmaceutical compositions for the treatment of brain and spinal cord diseases or degenerative disorders; pharmaceutical products for the treatment of all cognitive deficiencies and neurodegenerative diseases; sanitary products for medical purposes, namely for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; chemo-pharmaceutical products for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; biological preparations for medical use, namely for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; chemical preparations for medical or pharmaceutical use, namely for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; diagnostic products for medical use, namely for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; medicines for human medicine for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilitiesSECTION 71 - CANCELLED—
010Surgical, medical apparatus and instruments for the prevention, treatment and repair of neurodegenerative diseases; testing apparatus used for the treatment of all cognitive deficiencies and neurodegenerative diseases and for the treatment of brain and spinal cord diseases or degenerative disorders and for improving neurological abilitiesSECTION 71 - CANCELLED—
042Research and development of pharmaceutical products; biotechnology research and development; scientific and technological services as well as research and design services relating to the development of treatments for neurodegenerative diseases; biological research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseases, and the treatment of brain and spinal cord diseases or degenerative disorders, bacteriological research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseases, and the treatment of brain and spinal cord diseases or degenerative disorders, chemical research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseases, and the treatment of brain and spinal cord diseases or degenerative disorders; medical and parapharmaceutical research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseases, and the treatment of brain and spinal cord diseases or degenerative disorders; laboratory services and scientific research services particularly in the field of genetics; medical research in the field of brain diseases; technical information services relating to medical, pharmaceutical, parapharmaceutical and surgical activities; genetic research services; planning and development (design) of technical projects in the field of genetics; research and development in the field of medicine and genetics; scientific research and development services for the protection, treatment of brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; design and development of procedures and techniques for the treatment of brain and spinal cord diseases and for improving neurological abilities; clinical trials of treatments for neurodegenerative diseases, brain or spinal cord diseases, cognitive deficiencies and degenerative disorders and of diagnostic methods in the field of these diseases and geneticsSECTION 71 - CANCELLED—
044Medical care services for neurodegenerative diseases; medical care for the treatment of brain diseases; surgical treatments of the brain and spinal cord; therapy services; diagnosing and evaluating individuals with Alzheimer's disease or any other cognitive deficiencySECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 29, 2024INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Sep 6, 2024INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Sep 6, 2024INPCINVALIDATION PROCESSED—
Aug 30, 2024INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Dec 29, 2023C71TCANCELLED SECTION 71—
Jun 13, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Oct 28, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 21, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 21, 2017FIMPFINAL DISPOSITION PROCESSED—
Sep 13, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 13, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 28, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 28, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 25, 2017GPNXNOTIFICATION PROCESSED BY IB—
Mar 8, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 8, 2017OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 8, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 21, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 9, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 2, 2017DOCKASSIGNED TO EXAMINER—
Jan 31, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 31, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 31, 2017CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jan 27, 2017ALIEASSIGNED TO LIE—
Jan 10, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 10, 2017ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 10, 2017REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 29, 2016RFNTREFUSAL PROCESSED BY IB—
Jul 12, 2016MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 11, 2016RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 11, 2016RFRRREFUSAL PROCESSED BY MPU—
Jul 9, 2016RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 8, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 8, 2016DOCKASSIGNED TO EXAMINER—
Jul 8, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 7, 2016REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance